Latest Financial Performance News

Eildon Capital Group reported a $5.7 million net loss in FY25, weighed down by $8 million in one-off charges, while simplifying its portfolio and entering a new joint venture in North Queensland.

Eildon Capital Group reported a net loss of $5.7 million for FY2025, weighed down by significant one-off impairments, while pivoting to focused real estate investments with a new $20.8 million joint venture in Queensland.

Wagners Holding Company Limited reported a solid FY25 with revenue of $431.3 million, driven by growth in construction materials and composite fibre technologies, while reducing net debt by 29%.

WCM Global Growth Limited reported a robust FY2025 with a 31% portfolio return and raised its fully franked final dividend, alongside an upgraded progressive dividend policy and a shareholder-friendly DRP discount.

WCM Global Growth Limited reported a robust 53% rise in net profit for FY2025, driven by strong portfolio returns and a successful capital raise, prompting an increased final dividend and upward revision of future dividends.

Australis Oil & Gas reported a reduced half-year loss and positive cash flow despite lower production, while actively seeking a development partner for its Tuscaloosa Marine Shale assets.

Star Combo Pharma has reported a remarkable jump in profit for FY2025, driven by strong revenue growth and a settled insurance claim, while declaring its second dividend and planning production expansion.

Star Combo Pharma Limited reported a 7% increase in total revenue to $27.8 million for FY25, propelled by a 10% rise in its core OEM and Own Brands segment. The company’s profit before tax surged to $5.31 million, reflecting operational strength despite challenges in its Retail division.

Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.

Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.

Elanor Commercial Property Fund reported a solid FY25 with strong income and portfolio stability, while rejecting an unsolicited takeover bid from Lederer Group.